AZD4573

DRUG3 trials

Conditions

Acute Lymphocytic LeukemiaAcute Myeloid LeukemiaAdvanced Haematological MalignanciesB-cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeMultiple Myeloma

Phase 1

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

CompletedNCT03263637

AstraZenecaAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma +8

Start: 2017-10-24End: 2021-09-30Updated: 2021-10-22

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

CompletedNCT04630756

AstraZenecaAdvanced Haematological Malignancies

Start: 2021-02-17End: 2025-02-27Updated: 2025-04-09

Phase 2

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

CompletedNCT05140382

AstraZenecaRelapsed/Refractory Classical Hodgkins Lymphoma, Relapsed/Refractory Peripheral T-cell Lymphoma

Start: 2021-12-15End: 2024-02-16Updated: 2024-08-28

British Journal of Cancer2024-07-249 citations

AZD4573 in Combination with CHOP Increases Combination Benefit in Preclinical Peripheral T-Cell Lymphomas Models

Blood2023-11-022 citations

Transient CDK9 Inhibition with AZD4573 Effectively Induces Apoptosis in Burkitt Lymphoma As a Monotherapy in Pre-Clinical Models

Blood2023-11-02

P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

HemaSphere2023-08-013 citations

P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANALYSIS

HemaSphere2023-08-01

Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis

Hematological Oncology2023-06-012 citations

PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (<i>R/R</i> DLBCL)

Hematological Oncology2023-06-01

Abstract 5978: Cyclin dependent kinase 9 inhibitor AZD4573 induces cell death through DNA damage accumulation in breast cancer cells <i>in vitro</i>

Cancer Research2023-04-04

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Blood2022-11-158 citations

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

Blood2022-11-157 citations

AZD4573 Effectively Induces Apoptosis in r/r MCL As a Monotherapy or in Combination with Acalabrutinib

Blood2021-11-051 citations

AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.

2019-11-07213 citations

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Blood2018-11-29

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Blood2018-11-29

Abstract 310: AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1

Cancer Research2018-07-0111 citations

A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.

Journal of Clinical Oncology2018-05-2012 citations

AZD4573

Sponsors

Conditions

Phase 1

Phase 2

Related Papers